Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Longitudinal data analysis using generalized linear models

1986 • 17,084 citations

Signal Transduction through MAP Kinase Cascades

1998 • 1,762 citations

Activation of Raf as a Result of Recruitment to the Plasma Membrane

1994 • 979 citations

The stress-activated protein kinase pathways

1999 • 648 citations

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1996 • 444 citations

Signal transduction from multiple Ras effectors

1997 • 308 citations

Interaction of the Protein Kinase Raf-1 with 14-3-3 Proteins

1994 • 285 citations

Cell cycle targets of Ras/Raf signalling

1998 • 257 citations

Nucleic Acid Therapeutics: State of the Art and Future Prospects

1998 • 215 citations

Antisense oligonucleotides as therapeutic agents

1999 • 166 citations

Novel anticancer drug discovery

1999 • 150 citations

14-3-3 Facilitates Ras-Dependent Raf-1 Activation In Vitro and In Vivo

1998 • 138 citations

Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).

1997 • 137 citations

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C- raf kinase supports an antisense mechanism of action in vivo

1996 • 136 citations

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)

1999 • 131 citations

A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

2000 • 128 citations

Activity of Plasma Membrane-recruited Raf-1 Is Regulated by Ras via the Raf Zinc Finger

1997 • 117 citations

Ras‐related proteins in signal transduction and growth control

1995 • 115 citations

Antisense Aims for a Renaissance

1997 • 69 citations

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

1997 • 63 citations

Novel anti-cancer agents in development: exciting prospects and new challenges

1999 • 56 citations

Protein kinases: Six degrees of separation?

2000 • 52 citations

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

1997 • 49 citations

Pharmacokinetics and Tolerability of Intravenous Trecovirsen (GEM®91), an Antisense Phosphorothioate Oligonucleotide, in HIV‐Positive Subjects

1999 • 47 citations

Antisense Oligonucleotide Inhibition of Serine/Threonine Kinases

1999 • 22 citations

Antisense - time to shoot the messenger

1999 • 17 citations